Natera's (NTRA) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Natera's stock has received a "sell (D-)" rating from Weiss Ratings, indicating bearish sentiment from analysts regarding the company's performance.
• The company reported a revenue of $546.60 million for the last quarter but missed earnings per share estimates, affecting investor confidence.
• Analyst ratings are mixed, with one firm giving a Strong Buy rating and another issuing a Sell, contributing to an average consensus rating of "Moderate Buy" with a price target of $192.88.

Natera (NASDAQ:NTRA - Get Free Report)'s stock had its "sell (d-)" rating reissued by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently issued reports on the company. Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Wells Fargo & Company began coverage on shares of Natera in a research note on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price objective on the stock. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research note on Monday, July 28th. Stephens restated an "overweight" rating and issued a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Finally, Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $192.88.

Natera Stock Up 2.1%

Shares of NASDAQ NTRA opened at $172.09 on Wednesday. The stock has a market cap of $23.62 billion, a PE ratio of -90.10 and a beta of 1.74. Natera has a 52-week low of $117.27 and a 52-week high of $183.00. The business has a 50-day moving average price of $163.10 and a 200 day moving average price of $156.98.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera will post -1.49 earnings per share for the current year.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 14,083 shares of the business's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the transaction, the chief executive officer directly owned 154,072 shares in the company, valued at $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is owned by insiders.

Institutional Trading of Natera

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Jackson Hole Trust purchased a new stake in Natera during the first quarter worth about $29,000. Rakuten Securities Inc. boosted its holdings in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares in the last quarter. ORG Partners LLC purchased a new stake in Natera during the first quarter worth about $32,000. TCTC Holdings LLC boosted its holdings in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after buying an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.